Patent intelligence · US
US 10675303
Extracellular matrix compositions for the treatment of cancer
Extracellular matrix compositions for the treatment of cancer
Patent details — US 10675303
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 9, 2020
- Expiration
- Jun 4, 2040
- Applicant
- Adaptive Biologix, Inc.
- Claims
- 15
- CPC classes
- A61K, A61K31/282, A61K33/243, A61K35/12
Quick answer
US 10675303 (Extracellular matrix compositions for the treatment of cancer) is held by Adaptive Biologix, Inc.. Status: granted. Granted Jun 9, 2020. Expires Jun 4, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Adaptive Biologix, Inc.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/282, A61K33/243, A61K35/12, A61K35/13, A61K35/33
More from Adaptive Biologix, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12264187
Compositions and methods for targeted therapeutic delivery to bone
granted -
US 12263179
Lyme disease-associated T cell receptor-related methods
granted -
US 12266425
T cell receptor sequences diagnostic for COVID-19 and related compositions
granted -
US 12006517
Method for purification of bacteriophage particles
granted -
US 11911345
Phage dispensing system
granted -
US 11773138
Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
granted -
US 11390921
Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
granted -
US 11192923
Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
granted
Frequently asked questions
What is US patent 10675303?
US 10675303 (Extracellular matrix compositions for the treatment of cancer) is held by Adaptive Biologix, Inc.. Status: granted. Granted Jun 9, 2020. Expires Jun 4, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10675303?
Adaptive Biologix, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 10675303 expire?
Our index shows an expiration date of Jun 4, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.